Get the Stockscreener App
45.36
0.47%
0.21
After Hours:
45.50
0.14
+0.31%
Royalty Pharma Plc stock is traded at $45.36, with a volume of 2.55M.
It is up +0.47% in the last 24 hours and up +12.08% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$45.15
Open:
$45.2
24h Volume:
2.55M
Relative Volume:
0.67
Market Cap:
$19.43B
Revenue:
$2.35B
Net Income/Loss:
$1.30B
P/E Ratio:
25.94
EPS:
1.7487
Net Cash Flow:
$1.05B
1W Performance:
+0.55%
1M Performance:
+12.08%
6M Performance:
+26.07%
1Y Performance:
+35.89%
1-Day Range:
$44.88
$45.78
1-Week Range:
$44.67
$45.78
52-Week Range:
$29.66
$46.14
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
45.36 | 19.34B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.13 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
770.79 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
771.53 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
322.37 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
JPMorgan Chase & Co. Has $62.08 Million Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Performance Recap: What are Precision Drilling Corporations recent SEC filings showingWeekly Earnings Recap & Growth Focused Entry Point Reports - baoquankhu1.vn
Royalty Pharma (RPRX) Stock Report: Analysts See a 13% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
Tredje AP fonden Sells 39,546 Shares of Royalty Pharma PLC $RPRX - MarketBeat
HighTower Advisors LLC Raises Stock Position in Royalty Pharma PLC $RPRX - Defense World
Support Test: Is Royalty Pharma plc benefiting from innovation trends2025 Stock Rankings & Risk Managed Trade Strategies - baoquankhu1.vn
Can Royalty Pharma plc stock deliver strong Q4 earningsNew Guidance & Consistent Growth Stock Picks - mfd.ru
PTC’s Sephience Launch Appears Off To A Strong Start - Citeline News & Insights
Will Royalty Pharma plc outperform the market in YEARDay Trade & Safe Capital Allocation Plans - mfd.ru
CenterBook Partners LP Reduces Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Bought by Aberdeen Group plc - MarketBeat
5 Insightful Analyst Questions From Royalty Pharma's Q4 Earnings Call - Finviz
Heartland Advisors Inc. Purchases New Shares in Royalty Pharma PLC $RPRX - MarketBeat
5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call - Barchart.com
Stronger 2026 Guidance, Buybacks, and Manager Shift Might Change The Case For Investing In Royalty Pharma (RPRX) - simplywall.st
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighWhat's Next? - MarketBeat
Royalty Pharma : Q4 2025 Financial Results Call Transcript - marketscreener.com
Illinois Municipal Retirement Fund Sells 22,256 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M - MSN
Block Trades: Is Royalty Pharma plc likely to announce a buyback2025 EndofYear Setup & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Envestnet Asset Management Inc. Purchases 339,839 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma: 2025 Financial Performance And Strategic Outlook - Seeking Alpha
(RPRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Quarterly Recap: Is Royalty Pharma plc stock undervalued right now2025 Stock Rankings & Smart Allocation Stock Tips - baoquankhu1.vn
Royalty Pharma plc (NASDAQ:RPRX) Passed Our Checks, And It's About To Pay A US$0.235 Dividend - Yahoo Finance
Activity Recap: Does IONS stock benefit from AI growthJuly 2025 Update & High Conviction Trade Alerts - baoquankhu1.vn
Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions - MSN
Royalty Pharma Earnings Call Balances Strength And Risk - TipRanks
Royalty Pharma (RPRX) Margin Reset To 32.6% Tests Bullish Profitability Narratives - Sahm
New South Capital Management Inc. Purchases 31,694 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cookson Peirce & Co. Inc. Buys 338,623 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Will Royalty Pharma plc stock see insider buyingMarket Weekly Review & Growth Focused Stock Reports - mfd.ru
Risks Report: Is Royalty Pharma plc likely to announce a buybackWeekly Stock Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View (NASDAQ:RPRX) - Seeking Alpha
S P Trends: Is Royalty Pharma plc likely to announce a buybackWeekly Stock Recap & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Royalty Pharma price target raised to $51 from $45 at Goldman Sachs - TipRanks
Royalty Pharma plc (NASDAQ:RPRX) Q4 2025 Earnings Call Transcript - Insider Monkey
BofA Securities reiterates Buy rating on Royalty Pharma stock with $54 target - Investing.com Nigeria
BofA Securities Reiterates Buy Rating on Royalty Pharma (RPRX) - StreetInsider
Royalty Pharma stock hits 52-week high at 44.94 USD By Investing.com - Investing.com South Africa
Royalty Pharma's Disciplined Capital Allocation Approach and Appealing Market Growth Bolster Outlook - Morningstar
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight - GuruFocus
Royalty Pharma Q4 2025 slides: double-digit growth amid synthetic royalty expansion - Investing.com Nigeria
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
Royalty Pharma earnings beat by $0.22, revenue fell short of estimates - Investing.com UK
Royalty Pharma plc (RPRX) Reports Q4 results - StreetInsider
Earnings Call Summary | Royalty Pharma(RPRX.US) Q4 2025 Earnings Conference - 富途牛牛
Royalty Pharma earnings beat by $0.22, revenue topped estimates - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235 - simplywall.st
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):